02 October 2008
Biological properties of interleukin 2 and its role in pathogenesis of selected diseases--a review
Aldona Anna Kasprzak, Karolina Anna OlejniczakMed Sci Monit 2008; 14(10): RA179-189 :: ID: 869403
Abstract
Interleukin 2 (IL-2), or T-cell growth factor (TCGF), represents the first identified, fully-characterized, purified human interleukin. It is produced mainly by T helper (CD4+) lymphocytes, stimulates cell-mediated immune responses, controls growth and differentiation of B lymphocytes, and intensifies proliferation and activity of all cytotoxic cell clones. IL-2 is a growth factor in vitro and a mediator of self-tolerance in vivo, and therefore interests tumor immunotherapy investigators. The role of IL-2 in the cell cycle of neoplastic cells remains unclear. IL-2 inhibits growth of certain human tumor cells while proliferation of other cells remains intact or is even stimulated. Decreased IL-2 production is often observed in the more advanced clinical stages of human tumors, which provides rational for inclusion of recombinant IL-2 in the immunotherapy for some tumors. On the other hand, tumor cells themselves may produce IL-2 and promote tumor growth. This article summarizes the current physiological role of IL-2 and its role in the pathogenesis of select human diseases. Many papers (including reviews) pertain to the IL-2R receptor. The soluble form of the alpha subunit of the IL-2 receptor (sIL-2Ralpha) is elevated in most proliferative disturbances of the hematopoietic system and in many solid tumors. Special reference to the most important discoveries and our own experience in intracellular detection of IL-2 and IL-2Ralpha are included. IL-2 properties, cellular sources, and targets, including data on its expression in pathological conditions, continue to be supplemented. Attempts to treat tumors are also discussed, using modified varieties of therapy that use IL-2 itself and/or its receptor.
Keywords: Protein Subunits - metabolism, Receptors, Interleukin-2 - metabolism, Neoplasms - immunology, Interleukin-2 - metabolism, Immune System Diseases - immunology, Signal Transduction - physiology
Editorial
01 March 2024 : Editorial
Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-ThalassemiaDOI: 10.12659/MSM.944204
Med Sci Monit 2024; 30:e944204
In Press
18 Mar 2024 : Clinical Research
Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative StudyMed Sci Monit In Press; DOI: 10.12659/MSM.944136
21 Feb 2024 : Clinical Research
Potential Value of HSP90α in Prognosis of Triple-Negative Breast CancerMed Sci Monit In Press; DOI: 10.12659/MSM.943049
22 Feb 2024 : Review article
Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...Med Sci Monit In Press; DOI: 10.12659/MSM.943168
23 Feb 2024 : Clinical Research
A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...Med Sci Monit In Press; DOI: 10.12659/MSM.943732
Most Viewed Current Articles
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952